- Poster to be presented in alate-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday,November 9,2024
- Poster to be presented in alate-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday,November 9,2024
ROCKVILLE,Md.,Oct. 30,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a U.S.-based,global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced thepresentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111),a novel first-in-class Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody,at SITC 2024. The conference is being held in Houston,Texas,from November 6-10,2024.
Presentation Details:
Title: Optimal dose estimation using an integrated approach from Phase I data ofgivastomig,a novel Claudin18.2×4-1BB bispecific antibody
Poster #: 1474
Presenter: J.A. Yanez,I-Mab
Session: Poster Hall,George R. Brown Convention Center
Session Date: Saturday,2024
Session Time: 9:00 am CDT to 8:30 pm CDT,Level 1 – Exhibit Halls AB
A full copy of the poster will be available on the I-Mab website under the "Innovation,Publications & Presentations" tab on November 9,2024.
About Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin (CLDN) 18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig appears to maintain strong tumor binding and anti-tumor activity,attributable to a synergistic effect of proximal interaction with CLDN18.2 and 4-1BB,while minimizing liver toxicity and systemic immunotoxicity commonly seen with other emerging 4-1BB-based product candidates. In March 2022,the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for givastomig for the treatment of gastric cancer,including cancer of the gastroesophageal junction. A Phase 1b study is ongoing evaluating givastomig,in combination with standard-of-care nivolumab plus chemotherapy,in treatment-naïve patients with gastric cancers,including gastroesophageal cancer(NCT04900818).
The program is being jointly developed through a global partnership with ABL Bio,in which I-Mab is the lead party and shares worldwide rights,excluding China and South Korea,equally with ABL Bio.
AboutI-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based,global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director,Investor Relations
